Modern Biosciences teams up with Bradford University on novel anticancer
This article was originally published in Scrip
The Institute of Cancer Therapeutics at the University of Bradford has granted the UK firm Modern Biosciences (MBS) an exclusive 12-month option to license the university's targeted vascular disrupting agent. The candidate has potential to overcome tumour selectivity and systemic toxicity associated with many chemotherapeutic agents and represents a new approach in tackling cancer, MBS says. MBS will license the technology after it has completed certain confirmatory studies and plans to fund and manage the development of the project. The two establishments will share revenues generated by the deal. This is MBS's fourth agreement with UK academia - it previously secured deals with the Universities of Aberdeen, Dundee and Manchester.
You may also be interested in...
Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.
Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.